ABSTRACT: Background. Incidence rates for oral tongue squamous cell carcinoma (SCC) are steadily rising worldwide. Methods. All patients diagnosed with primary oral tongue SCC at the 5 university hospitals in Finland from 2005 to 2009 were studied. The mean follow-up time was 43 months (median, 54 months; range, 0-111 months). Results. Three hundred sixty patients with primary oral tongue SCC were identified. Treatment with curative intent was provided for 328 patients (91%). The 5-year disease-specific survival (DSS) rates were as follows: stage I 87%; stage II 73%; stage III 69%; and stage IV 51%. The 5-year recurrence-free survival in general has improved from 47% in our previous published series (1995)(1996)(1997)(1998)(1999) to 65% in the current series (p < .001). Conclusion. The outcome of oral tongue SCC has significantly improved in Finland. However, the relatively high number of disease recurrences in patients with stage I and II disease, when compared with patients with stage III and IV disease, calls for an investigation of new treatment approaches.
INTRODUCTION
Oral cancer (including lip cancer) constitutes an important part of the global burden of cancer as it accounts for approximately 2% of all cases worldwide. 1, 2 Smoking, excessive alcohol consumption, and human papillomavirus infection are the most commonly cited risk factors. 3, 4 However, other etiological factors, especially in young people with oral cancer, are still mainly unknown. 5, 6 Squamous cell carcinoma (SCC) accounts for 90% of all malignancies in the oral cavity. 7 The tongue is the most common location, with approximatively 40% of the cases. 8, 9 Increasing incidence trends of oral tongue SSC have been observed worldwide. 1, 2, 10, 11 Incidence rates vary considerably (0.8-8 per 100 000 per year) between countries, which is presumably because of diverse risk profiles among populations. Oral cancer is the 16th most common cancer in Finland, and, in the male population, the incidence of oral tongue SCC has increased: the ageadjusted incidence rate per 100,000 inhabitants was 1.2 in 2002 to 2006 and 1.7 in 2013 (http://www.cancerregistry. fi). Higher survival rates for oral tongue SCC have been reported for women than for men in the Nordic countries (Denmark, Finland, Iceland, Norway, and Sweden). The 5-year survival rate for men in this region has remained below 60% during the past 40 years. 11 Large tumor size, significant depth of invasion, intralesional removal, or insufficient resection margins and metastasis to regional lymph nodes are considered unfavorable prognostic factors. 12 The abundant vascular and lymphatic supply of the tongue apparently facilitates cancer cell invasion and metastasis.
Recommended treatment protocols for oral tongue SCC are still under debate, with surgery and radiotherapy being the conventional treatment modalities. Small, local tumors are mainly managed by local surgical resection. 13 Postoperative radiotherapy has been advocated for patients with high risk of disease recurrence. Combination therapy has been demonstrated to be more effective than surgery alone, 14 and some centers administer preoperative radiotherapy in their protocol. Furthermore, superior treatment results have been reported with adjuvant chemoradiotherapy compared to radiotherapy in the treatment of more widespread tumors. 15 A national treatment protocol for head and neck cancer management in Finland has been set up and is continually updated by the Finnish Head and Neck Oncology Working Group. The purpose of this study was to investigate the implemented treatment modalities and outcomes for oral tongue SCC in Finland during the years 2005 to 2009. The results were also compared with previously published Finnish oral tongue SCC data of 235 patients from the years 1995 to 1999. 13 
PATIENTS AND METHODS
All patients diagnosed with primary oral tongue SCC at the 5 university hospitals in Finland during the 5-year period between January 1, 2005, and December 31, 2009, were included in this study. Patients were identified from hospital pathology and surgery registries by using the International Classification of Disease-10 diagnosis codes (C02.0, C02.10, C02.11, C02.2, C02.3, and C02.9). Only histologically confirmed primary cases of epithelial cancer located in the mobile tongue were included. Patient clinicopathological data obtained from hospital records were reviewed and information was collected on the following: age, sex, smoking and drinking habits before diagnosis, date of pathological diagnosis, tumor location, clinical and pathological TNM classifications, tumor histopathology, intent of treatment, administered treatment (treatment of the primary tumor, reconstruction, neck dissection, radiotherapy, and chemotherapy), surgery date, start and end dates of radiotherapy, disease recurrence (location and date of diagnosis), date of last follow-up, and status at last follow-up. Details concerning dates and causes of death were acquired from Statistics Finland. Disease recurrence rates up to a 60-month follow-up timepoint were calculated for patients treated with curative intent and for whom disease control was reached (disease-free at 3 months after treatment). A clinical TNM classification was used in the previous Finnish oral tongue SCC treatment and survival study. 13 Thus, the recurrence and survival rates in this study were calculated also by using the clinical TNM classification data in addition to the pathological TNM classification data. All university hospitals in Finland use the Union for International Cancer Control TNM classification criteria for TNM and stage assignment (sixth and seventh editions, respectively, during the 1995-1999 and 2000-2005 periods), which ensures uniform TNM and classification assignment. The used pathological TNM classification in the analyses for recurrence and survival rates was based on postsurgical pathological findings. The clinical TNM classification was, however, applied for patients treated with preoperative or definitive radiotherapy. Statistical comparisons between patient characteristics and treatment modalities were performed using the Z-test for 2 population proportions and the Student's t test. Survival analysis after treatment completion was conducted using the Kaplan-Meier method with IBM SPSS version 20 (IBM, Armonk, NY). Statistical comparisons between survivals were conducted with the log-rank test. A multivariate Cox proportional hazards regression model was also used to analyze the risk factors associated with patient survival. Research permission for the study design was granted by the National Institute for Health and Welfare.
RESULTS
Three hundred sixty patients diagnosed with new oral tongue SCC were identified (52% were women; the mean age of all patients was 64.3 years; median, 65.6 years; range, 19-97 years). The mean follow-up time after treatment was 43 months (median, 54 months; range, 0-111 months). Twenty-nine patients (8%) were lost to follow-up during the first year. Clinical characteristics of the study group, along with the available data from the 1995 to 1999 patient cohort, are presented in Table 1 .
Most oral tongue SCCs were clinically diagnosed at stage I (n 5 148; 41%) and the majority of tumors (n 5 155; 43%) were T1. The pT1, pT2, pT3, and pT4 tumors represented, respectively, 61% (n 5 183), 25% (n 5 75), 9% (n 5 26), and 6% (n 5 17) of all surgically treated tumors (n 5 301), when excluding patients who were given preoperative radiotherapy. Clinically, 86 patients (24%) presented with cervical lymph node metastases (cN1 or cN2) and 1 patient had distant metastasis (stage IVc) at the time of diagnosis. The primary tumor was predominantly located on the lateral border of the tongue (78%); the ventral surface was the second most common location (12%).
Treatment with curative intent was provided for 328 patients (91%). The mean delay between diagnosis and surgery was 18 days (median, 15 days; range, 1-99 days). Correspondingly, the mean delay between diagnosis and start of radiotherapy or chemotherapy was 49 days (median, 43 days; range, 14-182 days). The mean time between surgery and start of radiotherapy or vice versa was 49 days (median, 48 days; range, 19-260 days). The primary tumor was surgically removed in 325 patients (99%; Table 2 ). Six (2%) total glossectomies were performed. Reconstructive surgery was performed for129 patients (39%). A neck dissection was performed electively for 156 patients (48%) and therapeutically for 66 patients (20%). Twenty-five bilateral neck dissections were performed. A sentinel lymph node biopsy was performed for 35 patients (11%) and subsequently resulted in a therapeutic neck dissection in 18 cases. Cervical lymph node metastases were pathologically diagnosed after completed neck dissection in 86 patients (39%), 44 (51%) of whom had been clinically classified as N0 (false-negative cervical nodes). T1 and T2 tumors constituted 32% (n 5 14) and 50% (n 5 22) of the false-negative cases. Of the 136 patients with histologically negative neck nodes, 112 (82%) had been correctly identified as such upon clinical and radiological examination. The positive and negative predictive values for diagnosis of neck metastatic disease were 64% and 72%, respectively. Twenty-four (9%) and 108 patients (33%) received preoperative and postoperative intensity-modulated radiotherapy as part of the curative treatment. The mean treatment duration was 45 days (median, 45 days; range, 14-74 days), and the mean total radiation dose to the primary tumor and to the neck were 59.6 Gy (median, 60 Gy; range, 16-70 Gy) and 54 Gy (median, 54 Gy; range, 16-70 Gy) in 1.8 to 2 Gy fractions. Adjuvant cisplatin-based chemotherapy and radiotherapy were administered to 55 patients (17%). One patient (diagnosed with clinical stage I) was treated with radiotherapy alone and 2 patients (diagnosed with clinical stages III and IV) were treated with chemoradiotherapy alone (Table 2) .
Forty-six patients (88%) diagnosed with clinical stage III disease were treated with curative intent. Approximately one third of the patients (n 5 16; 35%) in this group received radiotherapy and 15 patients (33%) were treated with chemoradiotherapy after curatively intended surgery. Twenty-four (49%) and 10 (20%) of the patients with stage III disease (pTNM classification, n 5 49) received postoperative radiotherapy and chemoradiotherapy in combination with surgery, respectively. There was no significant difference in the disease recurrence rate between patients with stage III treated by surgery and radiotherapy and patients treated by surgery and chemoradiotherapy. Patients with clinical stage IV disease treated with curative intent (n 5 44; 68%) mainly received combined treatment that either consisted of surgery and radiotherapy (n 5 14; 32%) or surgery and chemoradiotherapy (n 5 22; 50%). Forty-eight patients were diagnosed with stage IV disease using the pTNM classification. Twenty (42%) and 25 patients (52%) in this group, respectively, received radiotherapy and chemoradiotherapy after curatively intended surgery.
Disease control after primary phase curatively intended treatment was accomplished in 95% of the patients (n 5 312). Sixteen patients diagnosed with stage I disease (n 5 4; 2%), stage II (n 5 3; 7%), stage III (n 5 1; 2%), and stage IV (n 5 8; 14%) had disease persistence despite all the provided treatment. The rate for locoregional recurrence was 26% (n 5 81). Distant metastases were diagnosed in 17 patients (5%) during follow-up; 4 patients, all of whom had stage IV tumors, had an isolated distant recurrence. The recurrence rates for patients diagnosed with clinical stages I and II were locally 18% (n 5 26) and 19% (n 5 17), and regionally 13% (n 5 19) and 15% (n 5 13), respectively. Patients diagnosed with clinical stage I disease who were treated with curatively intended surgery who had additionally undergone an elective neck dissection or a sentinel node biopsy (n 5 67) had a significantly (p 5 .015) lower number of regional recurrences than patients treated only by surgical removal of the primary tumor (n 5 64). Disease recurrence rates according to stage and tumor classification for patients treated with curative intent are presented in Table 3 .
The 5-year overall survival (OS) rate for patients treated with curative intent was 61%. During the 5-year follow-up period, 58% of the patients (n 5 67) died of oral tongue SCC, 15% (n 5 17) died of cardiovascular diseases, and 10% (n 5 10) died of other cancers (2 patients died of other oral cavity cancers). The corresponding 5-year disease-specific survival (DSS) rate was 76%. There were no statistical differences between men and women or the different university hospitals in the OS and DSS rates. The 5-year DSS rates by stage and T ) classification of the tumor are presented in Table 4 . Survival rates calculated using the pathological TNM classification did not differ from the ones using the clinical TNM classification. DSS according to stage is also presented in Figure 1 . The 5-year recurrence-free survival in this patient series was 65%. The 5-year OS and DSS rates for patients younger than 40 years were both 86%. No statistical differences could be observed either in the stage distribution or the DSS rates, also when adjusting for other covariates, between different age groups. A multivariate Cox proportional hazards regression model was performed to examine the relationship between the following variables and treatment outcomes: sex, clinical stage, age, tobacco use before diagnosis, and heavy alcohol drinking (>24 units per week); the results of which are presented in Table 5 . Heavy alcohol drinking was, besides higher disease stage, statistically associated with decreased DSS (hazard ratio, 3.38; 95% confidence interval, 1.42-8.04; p 5 .006).
DISCUSSION
The incidence rate of oral tongue SCC is steadily rising, according to the Finnish Cancer Registry (http:// www.cancerregistry.fi). Similar increasing trends have been recently documented worldwide. 1, 2, 11 This nationwide study was conducted to investigate the treatment modalities and outcomes for 360 primary cases of oral tongue SCC in Finland during the 2005 to 2009 period, and to compare these results with our earlier cohort from the years 1995 to 1999. 13 The management of head and neck cancer is centralized to the university hospitals in Finland. Some patients with mobile tongue cancer may, however, have been treated at some of the larger nonuniversity central hospitals. The healthcare districts included in this study represent approximately two thirds of the Finnish population of 5.5 million. Stage  I  8 0  8 7  II  68  73  III  71  69  IV  33  51  T classification  T1  79  87  T2  65  72  T3  69  56  T4 27 38 When the patient cohorts for the years 1995 to 1999 and 2005 to 2009 were compared, no statistically significant differences could be found for the sex distributions (male/female ratio: 53/47 vs 48/52). However, the mean age of patients rose from 61.5 to 64.3 years (p 5 .025). A decrease in the proportion of patients in the age groups of 40 to 49 years (17% vs 33%) was complemented by an increase in the 60 to 69 years (17% vs 28%) group (p < .05). Throughout the study period, oral tongue SCC was usually diagnosed at an early clinical stage: patients with stage I disease covered 41% of the cases, and 43% of tumors were T1. An improvement in early detection of oral tongue SCC in Finland has occurred since the 1995 to 1999 period, during which time only 33% of patients were diagnosed with stage I disease and 34% of tumors were T1. Overall, the proportion of T1 tumors has increased, whereas the proportion of T2 tumors has decreased (p 5 .028). A similar trend could also be observed in the clinical stage distribution, which showed that the proportion of patients with stage II disease has increased whereas that of patients with stage III disease has decreased (p 5 .016). Surgical treatment remains the mainstay therapy for patients with clinical stages I and II oral tongue SCC: 89% of patients with stage I and 44% of stage II were treated by surgery alone. No statistically significant decrease in the rate of regional and locoregional recurrences in clinical stages I and II disease was observed in this study group when compared with the 1995 to 1999 cohort (13% vs 18% and 26% vs 32%).
Patients with clinical stage I disease treated with curative intent with an elective neck dissection or who underwent a sentinel node biopsy after primary phase treatment had a significantly lower rate of regional disease recurrence than patients treated by surgical removal of the primary tumor only (6% vs 20%; p 5 .015). A randomized controlled trial of 596 patients conducted by D'Cruz et al 16 reported better OS and DSS rates in early-stage oral cancer for patients who underwent an elective neck dissection. This emphasizes the importance of careful evaluation regarding the need for elective neck treatment in patients with stage I disease. However, elective neck dissection for treating early-stage oral tongue SCC also has its challenges: one has to consider the risk of occult spread to regional lymph nodes and the morbidity associated with neck dissection. Unfortunately, clinical and imaging examinations are far from perfect for the evaluation of neck status in patients with oral cancer. The sensitivity of clinical and imaging examination in detecting cervical lymph node metastases in this study was even lower than reported by others: 0.49 versus 0.64 to 0.83. Specificity (0.82) was within the range reported in other publications (0.80-0.96) related to head and neck cancer. 17, 18 This reveals the existing difficulty in the preoperative assessment of nodal status by clinical and conventional imaging methods.
Sentinel lymph node biopsy has emerged as a viable alternative diagnostic technique for neck staging in patients with cT1cN0 oral cancer. Negative predictive values of 97.5% to 100% have even been reported. 19, 20 Currently, sentinel lymph node biopsy is routinely performed in T1-T2N0 cancer of the mobile tongue in our centers. Some effort has also been directed toward finding histological prognostic markers, which could identify patients with a high-risk tumor who might benefit from multimodality treatment. 21, 22 However, the use of histomorphological or immunohistochemical markers in preoperative or intraoperative oral tongue SCC tissue samples is not yet a part of everyday clinical pathology practice.
Several studies have emphasized the need for a multidisciplinary treatment approach for improved survival of patients with advanced oral cancer. 12, 14, 23 Furthermore, benefits of combined therapy with adjuvant chemotherapy have been reported. 24 In the present study, 67% of patients with clinically staged (or 69% of pathologically staged) stage III and 82% of clinically staged (or 96% of pathologically staged) stage IV disease were treated by combination treatment, as opposed to 82% and 100% in our earlier patient cohort of the 1990s. Adjuvant chemotherapy was also more frequently used in combination with radiotherapy than in the previous series: 17% of patients or 41% of patients clinically staged (or 36% of pathologically staged) with stage III and IV were treated by chemoradiotherapy in combination with surgery. In contrast, only 1 patient had been similarly treated a The mean time between surgery and the start of radiotherapy, or vice versa was 49 days. The literature is controversial about the optimal treatment interval times. Although some studies have advocated an interval of less than 6 weeks for better locoregional control, 25 others have reported no significant differences. 26, 27 No differences could be observed in the rate of locoregional recurrence when comparing treatment interval times in our study.
It is noteworthy, that the disease recurrence rates for patients with pathological stage II, III, and IV tumors were rather similar at 30%, 34%, and 31%, respectively. Together with similar survival outcomes for stage II and III tumors, this raises the suspicion that possible understaging in some of the stage II tumors had occurred. An improved, more detailed staging protocol for these tumors is, therefore, warranted. The more aggressive treatment approach used for patients with stage III and IV disease may partially account for these observed outcomes. Four patients with clinical stage II disease did not undergo an elective neck dissection and were diagnosed with cervical metastatic disease during follow-up. It could be speculated that these patients had been clinically misdiagnosed as having a disease-free neck. The 5-year OS and DSS rates for patients treated curatively in the present study were 61% and 76%, respectively. The corresponding rates in the 1995 to 1999 patient cohort were lower; 53% and 64%, respectively. The 5-year DSS improvement over the last series reached statistical significance (p 5 .018). Notable improvements in the 5-year DSS rates were observed in patients with stage I and stage IV disease (from 80% to 87% and from 33% to 51%, respectively), although these changes did not reach statistical significance.
Eight percent of patients in the current cohort were younger than 40 years of age at the time of diagnosis. Conflicting results have been reported with respect to survival in young patients with oral tongue SCC. 6, 28, 29 No disparities in DSS rates could be discerned between the different age groups in our study, which is supported by other studies. 28, 29 Women had a trend for longer DSS (hazard ratio, 0.46; 95% confidence interval, 0.21-1.00; p 5 .051) than men when adjusting for other covariates.
The 5-year recurrence-free survival for oral tongue SCC has generally improved from 47% in our previous series to 65% in the current series (p < .001). The survival and recurrence rates for oral tongue SCC at different university hospitals in Finland were similar. This can be attributed to the homogeneity of treatment level and the use of uniform tumor classification and national treatment guidelines throughout the entire country. Oral tongue SCC is usually diagnosed at an early stage (78% were clinically T1-T2 tumors) in Finland, which improves treatment outcome. Moreover, the short mean treatment delay of 20 days after diagnosis is likely to contribute to the improved prognosis. Nevertheless, the relatively high rate of disease recurrences for patients with stage I and II disease, 22% and 30%, respectively, calls for an improvement in the treatment approaches for oral tongue SCC. Histologic prognostic models might be a promising tool to detect high-risk patients for whom a more aggressive treatment approach could be beneficial and our current research focuses on these alternatives. 21, 22 Multimodality treatment involving adjuvant systemic therapy is advocated for patients with advanced disease.
